First-line cytoreductive treatment in MNPs

Dr Chris Hillis is an assistant professor in the Division of Oncology at McMaster University and hematologist at the Juravinski Hospital and Cancer Centre.

Which cytoreductive drug is your first-line option for the treatment of myeloproliferative neoplasms (MNPs)?

Chris Hillis, MD, MSc: Hydroxyurea or hydroxycarbamide remain the first-line cytoreductive therapies in MPNs in 2019. In young patients and in patients who wish to become pregnant who do require cytoreductive therapy we would use interferon as first-line [treatment].

See also

Tests to establish the cause of secondary polycythemia What tests are useful in establishing the cause of secondary polycythemia?
Management of patients with a low burden of JAK2 mutation and a history of thrombosis What is your approach in a patient with a low burden of JAK2 mutation without other diagnostic criteria for myeloproliferative neoplasms (MPNs)? Does this approach change if the patient has a history of thrombosis?
Genetic testing in the setting of high ferritin to exclude hemochromatosis Does a negative genetic test (C282Y and H63D) result exclude hemochromatosis in a patient with transferrin saturation >45% and ferritin level >1000?
Myeloproliferative neoplasms: Tasks for internists A lecture by Dr Chris Hillis, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine (MIRCIM) in May 2019.
Screening tests in patients with a suspected bleeding disorder What tests do you perform in a patient with a suspected bleeding disorder who has normal coagulation screening test results (platelet count, prothrombin time, partial thromboplastin time, thrombin time, fibrinogen)?

First-line cytoreductive treatment in MNPs

Social Media